Sleep Number Seeks Rescue Financing to Avoid Bankruptcy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Source: stocktwits
- Escalating Financial Crisis: Sleep Number reported a net loss of $59 million, significantly worse than last year's $5 million loss, indicating a deteriorating financial condition that raises bankruptcy risks.
- Stock Price Plunge: Shares of Sleep Number tumbled over 27% on Thursday, with a nearly 60% decline since March 18, reaching their lowest point since July 2009, reflecting market pessimism about the company's future.
- Exploring Financing Solutions: The company is in discussions with Guggenheim Partners regarding a potential rescue financing package that includes a $50 million priming loan, which could provide short-term financial relief to avoid bankruptcy.
- Operational Constraints: In its SEC 10K filing, Sleep Number expressed serious doubts about its ability to continue as a going concern, indicating potential difficulties in meeting financial obligations over the next year, which limits operational and financial flexibility and further impacts performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNBR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNBR
Wall Street analysts forecast SNBR stock price to rise
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 1.820
Low
5.00
Averages
5.50
High
6.00
Current: 1.820
Low
5.00
Averages
5.50
High
6.00
About SNBR
Sleep Number Corporation is a wellness technology company. The Company is engaged in designing, manufacturing, marketing, and distribution of sleep solutions. Its wellness technology platform helps solve sleep problems, whether it’s providing individualized temperature control for each sleeper through its Climate360 smart bed or applying its 24 billion hours of longitudinal sleep data and expertise to research with global institutions. The Company’s smart beds provide unmatched features, benefits and comfort that can lead to improved sleep health and wellness for both sleepers. Its active temperature balancing technology supports the ideal climate for both sleepers and solves a prevalent sleep challenge. The Company’s smart bed ecosystem includes a full line of FlexFit smart adjustable bases that seamlessly integrate with Sleep Number smart beds for an individualized sleep experience that is proven to deliver more restful sleep per night.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Disappointing Earnings: Sleep Number reported Q1 2026 results with a GAAP EPS of -$2.19, missing consensus estimates by $1.72, and revenue of $318.99 million, reflecting an 18.9% year-over-year decline, indicating severe financial distress for the company.
- Guidance Suspension: The company suspended its financial guidance, citing the engagement of Guggenheim Securities to evaluate strategic and financing options, suggesting it is actively seeking solutions to its financial challenges.
- Stock Price Plunge: Following the earnings report, Sleep Number's stock price fell by $0.55, or 22.45%, closing at $1.90 per share, reflecting investor concerns about the company's future prospects.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Sleep Number and its executives engaged in securities fraud or other unlawful business practices, potentially leading to further legal risks and financial losses.
See More
- Earnings Miss: Sleep Number's Q1 2026 financial results, released on May 12, revealed an 18.9% year-over-year decline in earnings per share, significantly missing consensus estimates and undermining investor confidence.
- Guidance Suspension: The company also suspended its financial guidance, further exacerbating market uncertainty regarding its future performance, which could impact investor decision-making.
- Stock Price Plunge: Following the earnings report, Sleep Number's shares plummeted by 22.45% on the same day, reflecting serious concerns about the company's financial health among investors.
- Legal Investigation Initiated: The Schall Law Firm has launched an investigation into whether Sleep Number issued false or misleading statements, potentially exposing the company to legal liabilities under securities laws.
See More
- Asure Software Risk: Asure Software (ASUR) has a trailing 12-month GAAP operating margin of -2.7%, with a revenue increase of 12.3% over the past two years, but an estimated sales growth of only 10.4% for the next year may restrict its ability to invest or reward shareholders.
- Sleep Number Profitability Decline: Sleep Number (SNBR) shows a trailing 12-month GAAP operating margin of -6.4%, with lagging same-store sales leading to a 44% annual drop in earnings per share, indicating a need for pricing and marketing strategy adjustments to stimulate demand.
- Sunrun Cash Flow Concerns: Sunrun (RUN) has a trailing 12-month GAAP operating margin of -1.7%, and its suboptimal cost structure along with cash-burning tendencies raises doubts about its ability to sustainably generate shareholder value, currently trading at $14.48 per share with a P/E ratio of 23.7.
- Market Environment Changes: These companies face increasing challenges amid heightened competition and funding difficulties, which could jeopardize their survival in the market, prompting investors to carefully assess their future prospects.
See More
- Declining Financial Performance: Sleep Number reported Q1 2026 results with a GAAP EPS of -$2.19, missing consensus estimates by $1.72, and revenue of $318.99 million, reflecting an 18.9% year-over-year decline, indicating severe profitability challenges for the company.
- Suspension of Financial Guidance: The company suspended its financial guidance, citing the engagement of Guggenheim Securities to evaluate strategic and financing options, which suggests a proactive approach to address its current financial difficulties.
- Significant Stock Price Drop: Following the earnings report, Sleep Number's stock price fell by $0.55, or 22.45%, closing at $1.90 per share, reflecting investor concerns regarding the company's future outlook and financial health.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sleep Number and its executives engaged in securities fraud or other unlawful business practices, potentially leading to a class action lawsuit, which could further exacerbate market concerns about its governance structure.
See More
- Liquidity Improvement: Sleep Number reached an agreement with existing lenders that adds $55 million in liquidity, including a new $25 million term loan, allowing time to focus on a long-term capital structure solution, thereby alleviating short-term financial pressures.
- Sales Performance Recovery: The company reported net sales of $319 million in Q1, which, while 19% lower year-over-year, aligns with analysts' expectations of $321 million, demonstrating resilience in the market recovery despite macroeconomic uncertainties.
- Product Line Success: The newly launched ComfortNext Lux mattress has become the top-selling product at approximately $4,000, and during the launch period, stores featuring the new lineup saw a 12% higher average revenue per unit (ARU) compared to previous products, indicating positive consumer reception.
- Effective Cost Control: Since the beginning of 2025, the company has identified over $235 million in annualized savings, with $200 million already executed, showcasing effective cost management that supports future profitability enhancements.
See More
- Severe Earnings Loss: Sleep Number reported a Q1 GAAP EPS of -$2.19, missing expectations by $1.72, indicating significant challenges in profitability for the company.
- Revenue Decline: The company generated $318.99 million in revenue for Q1, an 18.9% year-over-year decrease, failing to meet expectations and reflecting pressures from weak market demand and declining sales.
- Adjusted EBITDA Drop: Adjusted EBITDA fell to $6 million, down 74%, primarily driven by a decline in net sales and associated loss of fixed cost leverage, although partially offset by lower operating expenses.
- Deteriorating Cash Flow: Year-to-date, net cash used in operating activities was $8 million, down $5 million from last year, with free cash flow showing a use of $13.2 million, highlighting difficulties in cash flow management.
See More










